Table 3.

Summary of Clinical Studies.

Study	Reference	Pharmacological Treatment	Effect
Uppaluri et al., 2017	[50]	Trametinib	Reduction of Ras/MEK/ERK pathway activation and in clinical and metabolic tumor reponses.
Knochelmann et al., 2021	[54]	Nivolumab	Overall response rate of 33% with a median follow up of 2.23 years.
Goldberg et al., 2022	[55]	Nanoengineered Cisplatin (PRV111)	69% tumor reduction in ~7 days and over-87% response rate. No DLTs or drug-related serious adverse events were reported.
Ju et al., 2022	[56]	Camrelizumab + Apatinib	MPR rate of 40%. At 18 months, 10.5% of locoregional recurrence and 95% of survival rates.